Activist investor Starboard Value has reportedly built a stake in pharmaceutical giant Pfizer worth around a $1bn and is seeking to mount a turnaround at the struggling company, according to people familiar with the matter.
Pfizer Inc.
07 October 2024 08:02:45
Source: Sharecast
Several media outlets, citing unnamed sources, said Starboard was looking to implement a turnaround plan at the troubled drug maker after a falling share price amid weak post-Covid pandemic growth.
Former Pfizer chief executive Ian Read and ex-finance chief Frank D'Amelio, both of whom have expressed interest in supporting Starboard's turnaround, had been approached, the reports stated.
Pfizer spent $43bn on cancer drugmaker Seagen and last week pulled the lead sickle cell drug purchased as part of its $5.4bn buyout of biotech Global Blood Therapeutics, citing safety concerns.
Reporting by Frank Prenesti for Sharecast.com
N/A
ISIN:
N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes
Compare our accounts
If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.